GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Galmed Pharmaceuticals
Shares of Galmed, an Israeli biotech company focused on liver disease (LHD) treatments, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Pharma liver
Galmed Pharmaceuticals is an Israeli biopharmaceutical company developing a treatment for non-alcoholic steatohepatitis (NASH) and other liver diseases. We've categorized the company as "Pharma: Liver." The chart below shows investor sentiment in this competitive biotech segment.
Broad Market Index - GURU.Markets
Galmed Pharmaceuticals is an Israeli biopharmaceutical company developing drugs for the treatment of liver diseases such as nonalcoholic steatohepatitis. Its focus on this issue makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Galmed compares to it.
Change in the price of a company, segment, and market as a whole per day
GLMD - Daily change in the company's share price Galmed Pharmaceuticals
For Galmed Pharmaceuticals Ltd., which develops drugs to treat liver diseases, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Pharma liver
Galmed Pharmaceuticals is a biopharmaceutical company focused on treating liver diseases such as nonalcoholic steatohepatitis. This is a highly competitive and risky field. The chart below shows the segment's volatility, helping to assess how typical GLMD's dynamics are for this niche.
Daily change in the price of a broad market stock, index - GURU.Markets
Galmed Pharmaceuticals is an Israeli biotech company developing drugs for the treatment of liver diseases. Its shares are driven by news of clinical trials, adding an element of high scientific volatility typical of the biotech sector to the overall market picture.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Galmed Pharmaceuticals
Galmed Pharmaceuticals' year-to-date performance tells the story of its years-long struggle to develop a cure for nonalcoholic steatohepatitis (NASH). Its 12-month market cap is entirely dependent on clinical trial data. Its valuation reflects both the company's enormous potential market and the high risks associated with this complex disease.
Annual dynamics of market capitalization of the market segment - Pharma liver
Galmed, a late-stage biotech company, develops drugs for the treatment of liver diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this vast but complex field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Galmed Pharmaceuticals, focused on treating liver diseases such as non-alcoholic steatohepatitis (NASH), is working to address one of the most common healthcare challenges. Its year-over-year market capitalization reflects the high expectations of developing the first effective drug in this field and the intense competition.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Galmed Pharmaceuticals
Galmed is a late-stage Israeli biopharmaceutical company. Its monthly performance is entirely dependent on the results of its key clinical trials. Data on its liver disease drug is the key event shaping expectations.
Monthly dynamics of market capitalization of the market segment - Pharma liver
Galmed Pharmaceuticals Ltd. is an Israeli clinical-stage biopharmaceutical company developing an oral treatment for liver diseases such as non-alcoholic steatohepatitis (NASH). The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess the progress of its lead candidate in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Galmed Pharmaceuticals is a biotech company working on a treatment for liver disease. Its shares move with clinical trial news, not market cycles. Positive data can trigger explosive growth in a falling market, while failure can lead to a crash in a rising market. The chart demonstrates this complete independence from overall sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Galmed Pharmaceuticals
Galmed Pharmaceuticals, a biotech company focused on liver disease treatment (NASH), exhibits high volatility. Its weekly stock price is almost entirely dependent on clinical trial results, which investors eagerly await, as they determine the company's future.
Weekly dynamics of market capitalization of the market segment - Pharma liver
Galmed Pharmaceuticals is a biopharmaceutical company focused on treating liver diseases. Its short-term performance is almost entirely dependent on clinical trial results. This chart allows us to separate the impact of specific company news from general trends in the pharmaceutical industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Galmed Pharmaceuticals is a biotech company whose future depends on success in treating liver disease. Its shares are uncorrelated with the market. This chart clearly shows how news from the lab triggers movements that defy any market trends.
Market capitalization of the company, segment and market as a whole
GLMD - Market capitalization of the company Galmed Pharmaceuticals
Galmed Pharmaceuticals' market capitalization chart is the story of years of efforts to develop a drug for non-alcoholic steatohepatitis (NASH). Its chart is a rollercoaster of hopes and disappointments stemming from clinical trial results. Its current low price reflects investor skepticism after previous failures and a last-ditch attempt to rehabilitate its drug.
GLMD - Share of the company's market capitalization Galmed Pharmaceuticals within the market segment - Pharma liver
Galmed Pharmaceuticals is an Israeli biopharmaceutical company developing a drug for the treatment of liver diseases such as NASH. Its market share is small, but it is targeting a huge market. Its capitalization is a bet on the success of its clinical trials in a field where there are currently no approved drugs.
Market capitalization of the market segment - Pharma liver
This graph represents the combined weight of the entire biotech sector focused on liver diseases. For Galmed Pharmaceuticals, which is developing drugs for non-alcoholic steatohepatitis (NASH), this line represents a "silent epidemic." The rising graph reflects recognition of the scale of the problem and the huge potential market for the first company to develop an effective treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
Galmed Pharmaceuticals is developing a drug to treat obesity-related liver diseases. Its market capitalization is a bet on solving one of the most widespread healthcare problems. This represents the market share of the drug devoted to treating fatty liver disease.
Book value capitalization of the company, segment and market as a whole
GLMD - Book value capitalization of the company Galmed Pharmaceuticals
Galmed Pharmaceuticals develops drugs to treat liver diseases such as NAFLD. Its book value represents its financial resources for research. It consists of cash that allows the company to conduct clinical trials. How has this vital capital changed? The chart below shows.
GLMD - Share of the company's book capitalization Galmed Pharmaceuticals within the market segment - Pharma liver
Galmed Pharmaceuticals is a biotech company developing drugs for the treatment of liver diseases. Its scientific activities require a resource base: a laboratory for small molecule research and clinical trial management. The chart shows the company's share of the physical R&D infrastructure in this biopharma segment.
Market segment balance sheet capitalization - Pharma liver
Galmed Pharmaceuticals is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are knowledge- and capital-intensive. Galmed focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Galmed Pharmaceuticals' book value is not its plants, but rather the capital invested in clinical trials of its lead drug candidate for the treatment of nonalcoholic steatohepatitis (NASH), a serious liver disease. Its assets reflect the financial resources for this research. The chart illustrates its scale.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Galmed Pharmaceuticals
Galmed Pharmaceuticals is an Israeli biopharmaceutical company developing a drug for the treatment of liver diseases. Its market capitalization is a barometer of investor hopes for the success of its clinical trials in this large and complex field of medicine.
Market to book capitalization ratio in a market segment - Pharma liver
Galmed Pharmaceuticals is a biotech company developing a drug for the treatment of liver disease (NASH). Its high valuation on this chart reflects its bet on clinical trial success. This is a binary event: success will lead to a boom, while failure will lead to a crash.
Market to book capitalization ratio for the market as a whole
Galmed Pharmaceuticals focuses on treating liver diseases. Like many biotech companies, its market capitalization reflects investor expectations for successful clinical trials. This chart shows how willing the market is to "advance" research in anticipation of future breakthrough drugs.
Debts of the company, segment and market as a whole
GLMD - Company debts Galmed Pharmaceuticals
Galmed, an Israeli biopharmaceutical company developing treatments for liver diseases, is in the clinical stage and is entirely funded by raised capital. This chart illustrates the enormous financial requirements associated with late-stage clinical trials, which are critical to its success.
Market segment debts - Pharma liver
Galmed Pharmaceuticals is an Israeli clinical-stage biopharmaceutical company developing a drug for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. This chart shows how the company is raising capital to finance its lengthy and expensive clinical trials in one of the most complex and competitive areas of modern medicine.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Galmed Pharmaceuticals
Galmed Pharmaceuticals is an Israeli company developing a drug for the treatment of nonalcoholic steatohepatitis (NASH), a liver disease. Clinical trials in this area are complex and very expensive. This chart shows how much the company relies on debt financing to advance its lead candidate through the development stages.
Market segment debt to market segment book capitalization - Pharma liver
Galmed Pharmaceuticals is a biopharmaceutical company developing a treatment for liver diseases such as NASH. This is a large and complex therapeutic area. This chart shows how the company is funding its lengthy clinical trials, relating its debt structure to the broader biotech landscape.
Debt to book value of all companies in the market
Galmed Pharmaceuticals is a biopharmaceutical company developing a drug to treat nonalcoholic steatohepatitis (NASH), a liver disease. This represents a huge potential market, but clinical trials are expensive and risky. How dependent is the company on debt? This chart of total market debt provides context for assessing its financial strength.
P/E of the company, segment and market as a whole
P/E - Galmed Pharmaceuticals
Galmed Pharmaceuticals is a biopharmaceutical company developing an oral treatment for nonalcoholic steatohepatitis (NASH) and other liver diseases. This chart shows how investors value the company in the race to develop the first effective treatment for fatty liver disease. The valuation is highly sensitive to clinical trial data.
P/E of the market segment - Pharma liver
Galmed Pharmaceuticals is a biopharmaceutical company developing an oral treatment for nonalcoholic steatohepatitis (NASH), a serious liver disease. This chart illustrates the average valuation in the pharmaceutical sector, where investors perceive a huge potential market for liver disease treatments but also a high risk of clinical failure.
P/E of the market as a whole
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a treatment for non-alcoholic steatohepatitis (NASH) and other liver diseases. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether GLMD's high valuation is based on the enormous potential of the NASH market or is driven by overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Galmed Pharmaceuticals
Galmed Pharmaceuticals is a biopharmaceutical company developing a drug for the treatment of nonalcoholic steatohepatitis (NASH), a liver disease associated with obesity. This chart reflects investor expectations for the success of clinical trials in a huge and currently unserved market, where the first approved drug could become a blockbuster.
%20P%2FE%20Galmed%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Galmed-Pharmaceuticals&v=1772621545698 "Chart of the company's future (projected) P/E Galmed Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma liver
Galmed Pharmaceuticals is a biopharmaceutical company focused on developing a treatment for liver diseases such as non-alcoholic steatohepatitis (NASH). The chart shows average profitability expectations for the sector, helping to understand investors' confidence in Galmed's success in this complex and competitive field.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-liver&v=1772621545736 "Future (projected) P/E graph of the market segment - Pharma liver")
Future (projected) P/E of the market as a whole
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company developing a treatment for liver diseases such as non-alcoholic steatohepatitis (NASH). This market sentiment chart reflects investor willingness to fund long-term, risky biotech projects targeting large but complex markets.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772621545760 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Galmed Pharmaceuticals
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company developing a drug for the treatment of non-alcoholic steatohepatitis (NASH), a liver disease. Its financial performance is based on clinical trial expenses. This chart shows the investment in the fight against this widespread disease, which promises significant market potential if successful.
Profit of companies in the market segment - Pharma liver
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company developing a drug for the treatment of non-alcoholic steatohepatitis (NASH), a serious liver disease. This chart shows the overall profitability of the pharmaceutical sector, where developing the first approved drug for such a common condition could generate billions in revenue.
Overall market profit
Galmed Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of liver diseases. Its prospects depend entirely on the results of clinical trials and regulatory approvals. This process is isolated from macroeconomic trends, as shown by this chart. Demand for drugs for chronic liver diseases is stable.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Galmed Pharmaceuticals
Galmed Pharmaceuticals is a biopharmaceutical company developing an oral treatment for nonalcoholic steatohepatitis (NASH), a liver disease. Future revenue is entirely dependent on the results of late-stage clinical trials. This graph reflects the high risks and potentially enormous rewards of success in this large market.
%20profit%20of%20the%20company%20Galmed%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Galmed-Pharmaceuticals&v=1772621545850 "Graph of future (projected) profit of the company Galmed Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma liver
Galmed Pharmaceuticals is a biopharmaceutical company developing a drug for the treatment of nonalcoholic steatohepatitis (NASH), a serious liver disease. Given the prevalence of this disease, the potential market for a successful drug is enormous. This chart shows revenue projections for the pharmaceutical sector, helping to assess Galmed's potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-liver&v=1772621545871 "Graph of future (predicted) profits of companies in a market segment - Pharma liver")
Future (predicted) profit of the market as a whole
Galmed Pharmaceuticals is a biopharmaceutical company developing drugs to treat liver diseases such as NAFLD. Its prospects depend on success in clinical trials. The overall economic climate, reflected in this chart, influences the investment climate in the biotech sector, which influences Galmed's funding.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772621545875 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Galmed Pharmaceuticals
Galmed Pharmaceuticals is a biopharmaceutical company focused on treating liver diseases such as non-alcoholic steatohepatitis (NASH). It has no revenue at the clinical stage. This chart reflects solely investor confidence in its lead drug. Its value is a speculative estimate of the chances of success in treating this very common disease.
P/S market segment - Pharma liver
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing an oral treatment for liver diseases, specifically nonalcoholic steatohepatitis (NASH). This chart shows the average revenue estimate for the sector, providing insight into the market's perception of the prospects for treating this common disease.
P/S of the market as a whole
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company developing a drug for the treatment of non-alcoholic steatohepatitis (NASH), a liver disease. This chart shows that the valuation of such companies reflects the huge potential market for their drugs, justifying high multiples even without significant revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Galmed Pharmaceuticals
Galmed Pharmaceuticals is a biopharmaceutical company developing an oral treatment for nonalcoholic steatohepatitis (NASH), a liver disease. Estimating future revenue is crucial for the company, as NASH is a huge market with no approved treatments. The chart reflects investor expectations regarding the success of clinical trials and the commercial potential of its drug.
%20P%2FS%20Galmed%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Galmed-Pharmaceuticals&v=1772621546059 "The graph of the company's future (projected) P/S Galmed Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma liver
Galmed Pharmaceuticals is a biopharmaceutical company developing an oral treatment for non-alcoholic steatohepatitis (NASH) and other liver diseases. This chart reflects how investors view the company's future revenues relative to the pharmaceutical sector. It highlights market expectations regarding clinical trial results and the potential of its drug in the vast liver disease market.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20liver&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-liver&v=1772621546073 "Future (projected) P/S market segment graph - Pharma liver")
Future (projected) P/S of the market as a whole
Galmed Pharmaceuticals is developing a drug to treat nonalcoholic steatohepatitis (NASH), a common liver disease. The company's future depends entirely on the results of clinical trials in this highly competitive field. This chart of overall market expectations reflects investor confidence that addressing NASH will create a multibillion-dollar market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772621546118 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Galmed Pharmaceuticals
This chart shows the revenue of Galmed Pharmaceuticals, a clinical-stage biopharmaceutical company developing drugs for the treatment of liver diseases such as non-alcoholic steatohepatitis (NASH). There are currently no commercial revenues, and financial activity is driven by research and development expenses.
Sales of companies in the market segment - Pharma liver
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a treatment for liver diseases, specifically non-alcoholic steatohepatitis (NASH). It currently has no revenue. Its future value and revenue are entirely dependent on the success of its lead candidate, Aramchol.
Overall market sales
Galmed Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of liver diseases. Its success depends entirely on the results of clinical trials. This overall market situation is irrelevant to the company, whose value is determined by its scientific potential and ability to offer effective treatments to millions of patients.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Galmed Pharmaceuticals
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company developing an oral treatment for non-alcoholic steatohepatitis (NASH) and other liver diseases. Future revenue is dependent on the success of clinical trials. This chart reflects analyst forecasts for the potential market for NASH treatment and the company's chances of success.
%20sales%20of%20the%20company%20Galmed%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Galmed-Pharmaceuticals&v=1772621546305 "Schedule of future (projected) sales of the company Galmed Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma liver
Galmed Pharmaceuticals develops drugs to treat liver diseases such as non-alcoholic steatohepatitis (NASH). This chart shows the forecast for the pharmaceutical market. Are effective drugs for NASH expected to emerge, creating a multi-billion dollar market? This reflects the overall expectations for this segment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-liver&v=1772621546320 "Schedule of future (projected) sales of companies in the market segment - Pharma liver")
Future (projected) sales of the market as a whole
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company developing a treatment for liver diseases. Its value and prospects depend solely on the results of clinical trials. The general economic trends reflected in this chart have no impact on its research and development activities or patient demand for treatment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772621546338 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Galmed Pharmaceuticals
Galmed Pharmaceuticals is a biopharmaceutical company developing an oral treatment for nonalcoholic steatohepatitis (NASH), a serious liver disease. This chart shows its financial performance during clinical trials. Profitability depends on success in treating this complex disease, which could unlock a huge potential market.
Market segment marginality - Pharma liver
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a treatment for liver diseases, specifically non-alcoholic steatohepatitis (NASH). This chart reflects its financial position, where future profitability is entirely dependent on success in lengthy and costly clinical trials.
Market marginality as a whole
Galmed Pharmaceuticals is a biotech company focused on treating liver diseases. Its future depends on the results of clinical trials and strategic partnerships. This total return chart reflects the investment climate in the pharmaceutical industry. During periods of economic growth, investors are more willing to fund long-term R&D projects.
Employees in the company, segment and market as a whole
Number of employees in the company Galmed Pharmaceuticals
Galmed Pharmaceuticals is a clinical-stage biotech company developing a treatment for liver diseases such as non-alcoholic steatohepatitis (NASH). Its small staff is focused on conducting clinical trials. This graphic shows the team working to achieve key milestones that will shape the company's future.
Share of the company's employees Galmed Pharmaceuticals within the market segment - Pharma liver
Galmed Pharmaceuticals is a biopharmaceutical company focused on developing a treatment for liver diseases such as nonalcoholic steatohepatitis. Its primary focus is clinical research. This chart shows the company's market share, which is an indicator of the scale of its clinical programs and R&D team.
Number of employees in the market segment - Pharma liver
Galmed Pharmaceuticals is a biopharmaceutical company developing an oral treatment for nonalcoholic steatohepatitis (NASH) and other liver diseases. The chart reflects activity in the liver pharmaceutical sector. NASH is a "silent epidemic," and developing an effective treatment like the one Galmed is working on is one of the biggest challenges for the pharmaceutical industry.
Number of employees in the market as a whole
Galmed Pharmaceuticals is a biopharmaceutical company focused on treating liver diseases. Its development depends on the results of clinical trials. Unlike the broader labor market reflected in this chart, hiring at Galmed is a targeted investment in science, where every specialist contributes to the fight against chronic diseases.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Galmed Pharmaceuticals (GLMD)
Galmed Pharmaceuticals is a biotech company focused on treating liver diseases, specifically steatohepatitis (NASH). This chart demonstrates their intellectual capital valuation. It represents the market value per employee, which in biotech reflects the market's confidence in the success of their clinical trials and a future blockbuster.
%20of%20the%20company%20Galmed%20Pharmaceuticals%20(GLMD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Galmed-Pharmaceuticals-GLMD&v=1772621546482 "Chart of market capitalization per employee (in thousands of dollars) of the company Galmed Pharmaceuticals (GLMD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma liver
Galmed Pharmaceuticals (GLMD) is developing an oral drug for the treatment of liver diseases such as non-alcoholic steatohepatitis. In biopharma, this metric evaluates the potential of a single key product. A high valuation per employee often indicates that a company is close to success in treating a common disease, which promises billions in revenue.
%20by%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-liver&v=1772621546593 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma liver")
Market capitalization per employee (in thousands of dollars) for the overall market
Galmed Pharmaceuticals is a biotech company developing a drug to treat liver diseases such as non-alcoholic steatohepatitis (NASH). Its valuation is based on the success of clinical trials. The chart shows a high valuation per employee, as NASH is a huge market, and a successful drug could become a blockbuster.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772621546599 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Galmed Pharmaceuticals (GLMD)
Galmed is a clinical-stage biotech developing drugs for liver disease (NASH). This chart reflects net R&D workload. A negative R&D workload (loss per employee) is normal for biotech and reflects how much capital the company invests in each scientist leading expensive clinical trials.
%20Chart%20Galmed%20Pharmaceuticals%20(GLMD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Galmed-Pharmaceuticals-GLMD&v=1772621546684 "Company Profit Per Employee (in thousands of dollars) Chart Galmed Pharmaceuticals (GLMD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma liver
Galmed Pharmaceuticals is a biopharmaceutical company specializing in liver diseases. In the highly specialized pharmaceutical industry, a small but highly skilled team can create a blockbuster. This chart shows the financial value generated by each employee, which is an important indicator of the potential of their developments compared to other biotech companies.
%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-liver&v=1772621546719 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma liver")
Profit per employee (in thousands of dollars) for the market as a whole
Galmed Pharmaceuticals is a biotech company focused on treating liver diseases, specifically non-alcoholic steatohepatitis (NAS). It's an R&D company operating in the clinical trial cycle. This graph, showing average profitability, highlights how biotech, where all the value is in IP, differs from operating businesses that generate revenue through staff.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772621546804 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Galmed Pharmaceuticals (GLMD)
Galmed Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of liver diseases. At the clinical stage, this figure is insignificant. It reflects future potential: a successful drug for a market as large as liver diseases could generate enormous revenue, leading to explosive growth in this figure.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Galmed-Pharmaceuticals-GLMD&v=1772621546947 "Sales chart per company employee Galmed Pharmaceuticals (GLMD)")
Sales per employee in the market segment - Pharma liver
Galmed Pharmaceuticals is an Israeli clinical-stage biotech focused on the treatment of liver diseases, specifically non-alcoholic steatohepatitis (NASH). They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a benchmark for Galmed's R&D staffing efficiency compared to other biotechs.
Sales per employee for the market as a whole
Galmed Pharmaceuticals is a clinical-stage biotech company focused on developing a treatment for liver diseases such as NAFLD (NASH). This chart reflects their current status: the company is fully focused on R&D and has no commercial sales revenue. This is an investment in future potential.
Short shares by company, segment and market as a whole
Shares shorted by company Galmed Pharmaceuticals (GLMD)
Galmed (GLMD) is a biotech focused on treating liver diseases, particularly nonalcoholic steatohepatitis (NASH). It's a biotech "graveyard," where many giants have failed. This chart shows the number of short positions. The shorts reflect a bet that GLMD will also fail in clinical trials in this incredibly complex field.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Galmed-Pharmaceuticals-GLMD&v=1772621547154 "Short Shares Chart for the Company Galmed Pharmaceuticals (GLMD)")
Shares shorted by market segment - Pharma liver
Galmed Pharmaceuticals (GLMD) is a clinical-stage biotech company focused on developing an oral drug (Aramchol) for the treatment of liver diseases such as NASH. This chart aggregates short positions across the biotech sector. It reflects the high investor skepticism surrounding NASH drug development, where many have failed.
Shares shorted by the overall market
Galmed (GLMD) is a clinical-stage biotech. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing GLMD won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Galmed Pharmaceuticals (GLMD)
Galmed Pharmaceuticals (GLMD) is an Israeli biotech company developing Aramchol, a drug for the treatment of NAFLD (fatty liver disease) and fibrosis. It's a huge but complex market. This indicator measures the rate of price change. It shows when enthusiasm (above 70) or disappointment (below 30) about clinical trial data peaks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Galmed-Pharmaceuticals-GLMD&v=1772621547207 "RSI 14 indicator chart for the company's stock Galmed Pharmaceuticals (GLMD)")
RSI 14 Market Segment - Pharma liver
Galmed Pharmaceuticals is an Israeli biopharmaceutical company focused on liver disease treatment. Its lead drug (Aramchol) is being developed for the treatment of MASH (hepatitis). This chart measures the overall momentum in the liver biotech sector. It helps us understand whether GLMD's momentum is a response to its data or general hype.
RSI 14 for the overall market
Galmed Pharmaceuticals (GLMD) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GLMD (Galmed Pharmaceuticals)
Galmed Pharmaceuticals is an Israeli biopharmaceutical company developing an oral drug (Aramchol) for the treatment of NASH (MASH), a severe liver disease. This chart shows the speculative average price target from analysts, which is almost entirely based on their belief in the success of clinical trials and the potential of this huge market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GLMD-Galmed-Pharmaceuticals&v=1772621547238 "A chart showing analyst consensus forecasts for the expected stock price. GLMD (Galmed Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price GLMD (Galmed Pharmaceuticals)
Galmed is an Israeli biotech company that has placed a bet on developing a drug (Aramchol) to treat fatty liver disease (MASH). This chart measures the gap between the current price and the consensus target price. It shows the potential analysts see for their success in this "graveyard" of pharmaceutical developments.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GLMD-Galmed-Pharmaceuticals&v=1772621547248 "A chart showing the difference between the consensus forecast and the actual stock price. GLMD (Galmed Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma liver
Galmed (GLMD) is one of many biotech companies trying to create a "fatty liver pill" (NASH), the industry's "Holy Grail." This chart shows analysts' overall expectations for the entire liver disease pharma sector. It reflects whether experts believe this massive market will finally take off or whether it will remain a "graveyard" of R&D projects.
Analysts' consensus forecast for the overall market share price
Galmed Pharmaceuticals is an Israeli biotech company focused on treating fatty liver disease (NASH), one of the most complex and widespread diseases. This is a high-risk sector, where success depends on clinical trial results. This chart reflects the overall risk appetite in the market. For Galmed, which has yet to generate revenue, the overall analyst optimism (the rising chart) is critical for raising capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Galmed Pharmaceuticals
Galmed is a biotech company with an all-in-one bet on one of the most challenging targets in medicine: NASH (non-alcoholic steatohepatitis, fatty liver disease). Their drug candidate (Aramchol) is in R&D. This chart is a pure binary risk indicator. It doesn't reflect profit, but rather the market's speculative valuation of their (very risky) clinical data and their chances of success in this gold rush.
AKIMA Market Segment Index - Pharma liver
Galmed Pharmaceuticals (GLMD) is a biopharmaceutical company attacking one of the world's major silent epidemics—non-alcoholic steatohepatitis (MASH, formerly NASH). Their flagship drug, Aramchol, targets this complex liver disease. The chart shows the segment average index, allowing investors to weigh Galmed's high risk and potential breakthrough against the average expectations for the sector.
The AKIM Index for the overall market
Galmed Pharmaceuticals is an Israeli biotech company developing Aramchol, an oral treatment for liver disease (NASH/MASH). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this long-term R&D story compares to overall economic trends.
